

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Support for the amendments is found throughout the specification and claims as filed and no new matter is introduced by the amendments, which address formal issues.

Listing of Claims:

1 (Amended). A receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor, said receptor-specific nanocontainer comprising: a liposome having an exterior surface and an internal compartment; a gene ~~comprising a sufficient amount of genetic information to that~~ encodes a short hairpin RNA, said gene being located within the internal compartment of said liposome; a plurality of receptor targeting agents ~~which~~ that are capable of targeting said receptor; and a plurality of conjugation agents, wherein each targeting agent is connected to the exterior surface of said liposome via at least one of said conjugation agents.

2 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 1, wherein said short hairpin RNA comprises a nucleotide sequence that is antisense to at least a portion of an mRNA selected from the group consisting of: an mRNAs encoding the human epidermal growth factor receptor, an mRNA encoding a mutants of the EGFR, an mRNA encoding a mutant HER2, an mRNA encoding a mutant HER3, an mRNA encoding a mutant HER4, an mRNA encoding a mutant fibroblast growth factor receptor (FGFR), an mRNA encoding a mutant platelet derived growth factor receptor (PDGFR), an mRNA encoding a mutant insulin-like growth factor receptor-1 (IGFR1), an mRNA encoding a mutant transforming growth factor α (TGF- α), an mRNA encoding a mutant vascular endothelial growth factor (VEGF) or its receptor, VEGFR, an mRNA encoding an altered protein kinases kinase, an mRNA encoding including the Bcr-Abl, an mRNA encoding

c-Met, an mRNA encoding c-Kit, an mRNA encoding ras, an mRNA encoding raf, ~~or~~ and an mRNA encoding CdKs.

3 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 2, wherein said short hairpin RNA comprises a nucleotide sequence that is antisense to a portion of human epidermal growth factor receptor mRNA, said human epidermal growth factor receptor mRNA comprising a nucleotide sequence ~~having numbered~~ comprising nucleotides ~~from~~ 1 to 5532 of SEQ ID NO:21.

4 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 3, wherein said short hairpin RNA comprises a nucleotide sequence that is antisense to a portion of said human epidermal growth factor receptor mRNA that is located between ~~numbered~~ nucleotides 2300 and 3800 [.]of SEQ ID NO:21.

5 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 4 wherein said portion of said human epidermal growth factor receptor mRNA is located between ~~numbered~~ nucleotides 2500 and 3000 of SEQ ID NO:21.

6 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 5, wherein said portion of said human epidermal growth factor receptor mRNA is located between ~~number~~ nucleotides 2500 and 2600 of SEQ ID NO:21.

7 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 1, wherein said liposome exterior surface defines a sphere having a diameter of less than 200 nanometers.

8 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 1, wherein between 5 and 500 receptor-targeting agents are conjugated to the exterior surface of said liposome.

9 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 1, wherein said conjugation agent is selected from the group consisting of: polyethylene glycol, sphingomyelin and an organic polymers.

10 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 9, wherein the molecular weight of said conjugation agent is between 1000 and 50,000 Daltons.

11 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 1, wherein from 100 to 10,000 conjugation agents are attached to the exterior surface of said liposome.

12 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 1, wherein said targeting agents ~~are capable of targeting~~ target a receptor located on a solid tumor.

13 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 12, wherein said solid tumor is selected from the group consisting of: brain tumors, liver tumors, lung tumors, spleen tumors, breast tumors, kidney tumors, prostate tumors, ovary tumors, eye tumors, gastrointestinal tumors, bone tumors, blood tumors, endocrine tumors, skin tumors, ~~or~~ and lymph node tumors.

14 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 13, wherein said solid tumor is a brain tumor.

15 (Amended). The receptor-specific nanocontainer for delivering a gene encoding short hairpin RNA to a cell having a receptor according to claim 1, wherein said targeting agent ~~is capable of targeting~~ targets a receptor selected from the group consisting of: an insulin receptor, a transferrin receptor, an insulin-like growth factor receptor, a leptin receptor, and a low density lipoprotein receptor fibroblast growth factor receptor.

16 (Amended). A composition comprising the receptor-specific nanocontainer according to claim 1, and a pharmaceutically acceptable carrier for said receptor-specific nanocontainer.

17 (Amended). A composition comprising the receptor-specific nanocontainer according to claim 16 wherein [~~said cell to which said gene encoding said short hairpin RNA is to be delivered is located within an animal~~] the short hairpin RNA is expressible in a cell of an animal.

18-32 (Cancelled).